Clinical trials: Immune System Disease
Multiple Myeloma
Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma
Primary Objective: To determine if Multi Myeloma (MM) patients mobilized with granulocyte colony-stimulating factor (G-CSF) plus plerixafor 240 μg/kg are more likely to achieve a target number of greater than or equal to 6 x 10^6…
- Trial name
- NCT02221479
- Testing
- plerixafor GZ316455, Filgrastim
- Where
- 5 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Genzyme, a Sanofi Company
Gammopathy, Monoclonal
Monoclonal Gammopathy With Clinical Significance in Patients With and Without Haematological Malignancies in Finistère Between 2012 and 2017 (GammaClinik)
Clinical symptoms associated with monoclonal gammapathy have been primarily studied in hematological malignancy and rarely in MGUS and hemopathy.
- Trial name
- GammaClinik (NCT06559579)
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Brest
Lymphoma, Follicular, Non-Hodgkin Lymphoma
A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin
The objective of this study is to compare hematological toxicity, costs, health-related quality of Life (HR-QOL) and outcomes observed in real life in the Belgian Non-Hodgkin Lymphoma (NHL) population receiving 90Y-Zevalin, with…
- Trial name
- NCT01164696
- Testing
- [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Bayer
Chronic Inflammatory Demyelinating Polyneuropathy
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.
- Trial name
- NCT07032662
- Testing
- Imeroprubart
- Where
- 142 sites in United States, Argentina and 28 more
- Volunteers
- 162 people
- Sponsor
- Immunovant Sciences GmbH
Asthma, Chronic School Absenteeism
Home Visits to Optimize Medical and Educational Success Among Sacramento Schoolchildren With Asthma
This study will establish a multi-disciplinary home visitation team consisting of a medical provider and school teacher or staff member, and will evaluate whether a series of visits from this team will help decrease school…
- Trial name
- NCT03335046
- Testing
- Home Visit, Standard Care
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, Davis
Rheumatoid Arthritis
Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis
The purpose of this study is to evaluate the long-term safety of subcutaneous (SC) self-injections (by the subject or subject's family member) of adalimumab in adult Japanese subjects with Rheumatoid Arthritis in an open-label…
- Trial name
- NCT00603993
- Testing
- Adalimumab
- Where
- 16 sites in Japan
- Volunteers
- 88 people
- Sponsor
- Abbott
Insulin Resistance
Novel Therapy for Glucose Intolerance in HIV Disease
This research is to investigate the nutritional supplement chromium picolinate. The investigators are testing to see how effective this supplement is in treating insulin resistance associated with HIV disease.
- Trial name
- NCT02006914
- Testing
- Chromium Picolinate
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Stony Brook University
Pancreatitis, Pancreatic Neoplasms
Follow-up Study of Complications of Acute Pancreatitis
This is a follow-up study focusing on long-term complications of acute pancreatitis. The primary purposes include: 1. To assess the incidence of type 2 diabetes mellitus（2-DM）,impaired glucose tolerance, metabolic abnormalities…
- Conditions
- Pancreatitis, Pancreatic Neoplasms, Metabolic Diseases, Hypertension, Portal
- Trial name
- FSCAP (NCT02305914)
- Where
- China
- Volunteers
- 1,300 people
- Sponsor
- The First Affiliated Hospital of Nanchang University
Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)
This single arm study will assess the efficacy and safety of rituximab in combination with fludarabine and cyclophosphamide, followed by rituximab maintenance therapy, as first line treatment of participants with CLL.
- Trial name
- NCT00545714
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 33 sites in Spain
- Volunteers
- 86 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Chronic Myeloproliferative Disorders
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict whether patients undergoing donor stem cell transplant will develop acute graft-versus-host disease.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00651716
- Testing
- flow cytometry, laboratory biomarker analysis, Data Collection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Chronic Lymphocytic Leukemia, B-Cell Lymphoma
Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
This study will evaluate the safety, antitumor activity and preliminary pharmacokinetics of an investigational drug product, DTRMWXHS-12, in patients with chronic lymphocytic leukemia or other B-cell lymphomas.
- Trial name
- NCT02900716
- Testing
- DTRMWXHS-12, DTRM-505, DTRM-555
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Zhejiang DTRM Biopharma
Allergic Rhinitis
Cellulose Powder Against Grass Pollen Allergic Rhinitis
Background: A nasally applied cellulose powder is increasingly used in many countries as a remedy for allergic rhinitis. In 2009, a 4-week study in birch pollen-allergic children showed a reduction in nasal symptoms.
- Trial name
- CPARGPDBPC (NCT03039816)
- Testing
- Nasaleze
- Where
- 3 sites in Sweden, Ukraine
- Volunteers
- 108 people
- Sponsor
- Nasaleze International Ltd
Type 1 Diabetes
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's…
- Trial name
- NCT02488616
- Testing
- 5-day intervention with single-hormone closed-loop strategy, 5-day intervention with sensor-augmented pump therapy, Insulin pump
- Where
- Canada
- Sponsor
- Institut de Recherches Cliniques de Montreal
Type 1 Diabetes Mellitus
MSC Administration for the Management of Type 1 Diabetic Patients
The purpose of this study is to evaluate whether the administration of multipotent stromal cell also referred as to mesenchymal stem cells (MSCs), modified Type 1 Diabetes progression.
- Trial name
- DMT1-MSC (NCT02893306)
- Testing
- MSCs
- Where
- Chile
- Volunteers
- 10 people
- Sponsor
- Universidad del Desarrollo
Diabetes Mellitus, Type 1, NASH
Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes
Background: Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD) that can precipitate to advanced fibrosis and leads to cardiovascular morbidity and mortality.
- Trial name
- NCT06348706
- Testing
- Dipeptidyl peptidase 4 (DPP-4) inhibitor
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Lymphoma
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as yttrium Y 90 ibritumomab tiuxetan and rituximab can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00062114
- Testing
- rituximab, yttrium Y 90 ibritumomab tiuxetan
- Where
- 94 sites in United States
- Volunteers
- 84 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Allergy
The Prolonged Effect of Consumption of a Partially Hydrolyzed Infant Formula During the First 6 Months of Life on the Development of Allergic Manifestations At 5 Years of Age
The present study is a 5-year follow-up of the Allergy Reduction Trial (A.R.T.) birth cohort study of 551 infants at high-risk for allergy. The A.R.T.
- Trial name
- NCT05418491
- Testing
- No intervention is used in the current study. Interventions were given in the original A.R.T. study
- Where
- 3 sites in Bulgaria, Cyprus and 1 more
- Volunteers
- 455 people
- Sponsor
- FrieslandCampina
HIV Infection
Combination Drug Treatment of Pediatric HIV Infection
This study will test the safety and effectiveness of hydroxyurea, an anti-cancer drug, given together with the anti-HIV drugs didanosine, stavudine and efavirenz for treating children infected with human immunodeficiency virus…
- Trial name
- NCT00001818
- Testing
- Hydroxyurea
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
B-Cell Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma
Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies
Despite advancement in chemotherapy, radiotherapy and haematopoietic stem cell transplant (HSCT), and the recent introduction of more targeted therapies, a substantial proportion of patients with B-cell malignancies, such as…
- Trial name
- NCT02315118
- Testing
- T-cell therapy + Rituximab + IL-2
- Where
- Singapore
- Volunteers
- 18 people
- Sponsor
- National University Hospital, Singapore
Pemphigoid, Bullous, Adrenal Insufficiency
Screening for Adrenal Insufficiency During Dermocorticoid Reduction in Bullous Pemphigoid (BP)
The braking of the corticotropic axis is well established during the induction phase of superpotent topical corticosteroid therapy (clobetasol propionate) in bullous pemphigoid (BP).
- Trial name
- PB-DEPIST (NCT06148090)
- Testing
- clobetasol decreasing measurement
- Where
- 5 sites in France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bordeaux
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.